Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2010 1
2011 1
2013 3
2014 2
2015 2
2016 8
2017 2
2018 1
2019 3
2020 2
2021 2
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J. Sestak I, et al. J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11. doi: 10.1093/jnci/djt244. Epub 2013 Sep 12. J Natl Cancer Inst. 2013. PMID: 24029245 Free PMC article.
BACKGROUND: Adjuvant endocrine therapy beyond 5 years reduces recurrence in patients with estrogen receptor-positive breast cancer. We have previously shown that immunohistochemical markers (IHC4) and two gene expression profile tests ( …
BACKGROUND: Adjuvant endocrine therapy beyond 5 years reduces recurrence in patients with estrogen receptor-positive …
Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates.
González-Hurtado D, Rivero S, Samamé Pérez-Vargas JC, Petracci FE. González-Hurtado D, et al. Breast Cancer (Auckl). 2023 Aug 23;17:11782234231192780. doi: 10.1177/11782234231192780. eCollection 2023. Breast Cancer (Auckl). 2023. PMID: 37637230 Free PMC article. Review.
Prognostic and predictive factors for early and late distant distance recurrence risk in estrogen-receptor positive and HER2-receptor negative early breast cancer are well known, but not all these variables work equal …
Prognostic and predictive factors for early and late distant distance recurrence risk in estrogen-rece …
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, Ishida N, Horii R, Yamazaki K, Miyoshi Y, Yasojima H, Tomioka N; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Yamashita H, et al. Breast Cancer. 2016 Nov;23(6):830-843. doi: 10.1007/s12282-015-0649-0. Epub 2015 Oct 14. Breast Cancer. 2016. PMID: 26467036 Free article.
BACKGROUND: Most studies analyzing prognostic factors for late relapse have been performed in postmenopausal women who received tamoxifen or aromatase inhibitors as adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer. .. …
BACKGROUND: Most studies analyzing prognostic factors for late relapse have been performed in postmenopausal women who receive …
Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Ma CX, Bose R, Ellis MJ. Ma CX, et al. Adv Exp Med Biol. 2016;882:125-54. doi: 10.1007/978-3-319-22909-6_5. Adv Exp Med Biol. 2016. PMID: 26987533 Review.
The estrogen-dependent nature of breast cancer is the fundamental basis for endocrine therapy. ...While MammaPrint and Oncotype Dx are most predictive of recurrence risk within the first 5 years of diagnosis, Prosigna, Breast Cancer …
The estrogen-dependent nature of breast cancer is the fundamental basis for endocrine therapy. ...While MammaPrint and …
Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients.
Han HH, Lee SH, Kim BG, Lee JH, Kang S, Cho NH. Han HH, et al. Medicine (Baltimore). 2016 Feb;95(8):e2909. doi: 10.1097/MD.0000000000002909. Medicine (Baltimore). 2016. PMID: 26937933 Free PMC article.
Estrogen receptor-positive (ER+) breast cancer (BCa) often recurs after long latency, and is known to favor bone as a metastatic site. ...In multivariate analysis, ER and lymph node involvement status were significant prognostic factors f …
Estrogen receptor-positive (ER+) breast cancer (BCa) often recurs after long latency, and is known to fav …
Competing Nomogram for Late-Period Breast Cancer-Specific Death in Patients with Early-Stage Hormone Receptor-Positive Breast Cancer.
Zhu J, Zheng H, Ge C, Lin H, Yu K, Wu L, Li D, Zhou S, Tang W, Wang Q, Zhang X, Jin X, Xu X, Du J, Fu J. Zhu J, et al. Clin Breast Cancer. 2022 Apr;22(3):e296-e309. doi: 10.1016/j.clbc.2021.08.008. Epub 2021 Aug 31. Clin Breast Cancer. 2022. PMID: 34627728
BACKGROUND: More than half of early breast cancer recurrences occur after 5 years from the initial diagnosis. ...Univariate and multivariate analyses based on the competing risk regression model were used to evaluate predictive factors for high …
BACKGROUND: More than half of early breast cancer recurrences occur after 5 years from the initial diagnosis. ...Univar …
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer.
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A, Cuzick J. Dowsett M, et al. Clin Cancer Res. 2015 Jun 15;21(12):2763-70. doi: 10.1158/1078-0432.CCR-14-2842. Clin Cancer Res. 2015. PMID: 26078431
EXPERIMENTAL DESIGN: We conducted a retrospective assessment of the relationship between (i) the individual genes and gene modules of the Recurrence Score and (ii) early (0-5 years) and late (5-10 years) recurrence rates in 1,125 postmenopausal patients with …
EXPERIMENTAL DESIGN: We conducted a retrospective assessment of the relationship between (i) the individual genes and gene modules of the …
The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer.
Fukuoka M, Ichikawa Y, Osako T, Fujita T, Baba S, Takeuchi K, Tsunoda N, Ebata T, Ueno T, Ohno S, Saitoh N. Fukuoka M, et al. Cancer Sci. 2022 Jul;113(7):2336-2351. doi: 10.1111/cas.15373. Epub 2022 May 3. Cancer Sci. 2022. PMID: 35415910 Free PMC article.
The recurrence risk of estrogen receptor (ER)-positive breast cancer remains high for a long period of time, unlike other types of cancer. ...Our findings highlight a new role of nuclear long noncoding RNAs and their clinical potential as pre …
The recurrence risk of estrogen receptor (ER)-positive breast cancer remains high for a long period of time, unl …
Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, Stål O, Brufsky AM, Sgroi D, Erlander MG. Zhang Y, et al. Clin Cancer Res. 2013 Aug 1;19(15):4196-205. doi: 10.1158/1078-0432.CCR-13-0804. Epub 2013 Jun 11. Clin Cancer Res. 2013. PMID: 23757354
PURPOSE: Residual risk of relapse remains a substantial concern for patients with hormone receptor-positive breast cancer, with approximately half of all disease recurrences occurring after five years of adjuvant antiestrogen therapy. EXPERIMENT …
PURPOSE: Residual risk of relapse remains a substantial concern for patients with hormone receptor-positive breast c …
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Pece S, Sestak I, Montani F, Tillhon M, Maisonneuve P, Freddi S, Chu K, Colleoni M, Veronesi P, Disalvatore D, Viale G, Buus R, Cuzick J, Dowsett M, Di Fiore PP. Pece S, et al. Eur J Cancer. 2022 Mar;164:52-61. doi: 10.1016/j.ejca.2022.01.003. Epub 2022 Feb 15. Eur J Cancer. 2022. PMID: 35172273 Free article. Clinical Trial.
OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist therapy decision-making in oestrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast ca …
OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist therapy decision-making in …
28 results